Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Spruce Biosciences, Inc is a biotechnology business based in the US. Spruce Biosciences shares (SPRB) are listed on the NASDAQ and all prices are listed in US Dollars. Spruce Biosciences employs 15 staff and has a market cap (total outstanding shares value) of USD$463.3 million.
|52-week range||USD$15 - USD$31.25|
|50-day moving average||USD$21.3026|
|200-day moving average||USD$21.7982|
|Wall St. target price||USD$33.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$463.3 million|
TTM: trailing 12 months
There are currently 377,342 Spruce Biosciences shares held short by investors – that's known as Spruce Biosciences's "short interest". This figure is 1.3% down from 382,454 last month.
There are a few different ways that this level of interest in shorting Spruce Biosciences shares can be evaluated.
Spruce Biosciences's "short interest ratio" (SIR) is the quantity of Spruce Biosciences shares currently shorted divided by the average quantity of Spruce Biosciences shares traded daily (recently around 37734.2). Spruce Biosciences's SIR currently stands at 10. In other words for every 100,000 Spruce Biosciences shares traded daily on the market, roughly 10000 shares are currently held short.
To gain some more context, you can compare Spruce Biosciences's short interest ratio against those of similar companies.
However Spruce Biosciences's short interest can also be evaluated against the total number of Spruce Biosciences shares, or, against the total number of tradable Spruce Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Spruce Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Spruce Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0211% of the tradable shares (for every 100,000 tradable Spruce Biosciences shares, roughly 21 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Spruce Biosciences.
Find out more about how you can short Spruce Biosciences stock.
We're not expecting Spruce Biosciences to pay a dividend over the next 12 months.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.